3 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
The objectives of the study are to assess whether:(1) SNP will reduce the occurrence of psychomimetic side effects during exposure to low-dose ketamine;(2) SNP will reduce the ketamine-induced increase in blood pressure and cardiac output;(3) SNP is…
Determination of possible Alzheimer pathology in the brain and to follow-up participants over time (by means of another research protocol). In addition, its [18F]-label with a half-life of 110 minutes will enable use in hospitals without an on-site…